Project Origin
Discovery of a novel biomarker of ischemia
iSCOR is based on the quantificaction of blood levels of glycosylated Apolipoprotein J (ApoJ-Glyc)
Link to publication
Discovery of the biomarker in samples of patients in the early ischemic phase
ApoJ-Glyc was identified as a potential novel marker of the early stages of ischemia in a Discovery proteomic study analysing serum samples of patients in the early phase of a cardiac ishcmemic event. Specifically, a decrease in the levels of glycosylated ApoJ forms was detected.
Development of the first iSCOR immunoassay and retrospective clinical validation
After the discovery of the novel biomarker, we developed a novel immunoassay for the quantification of ApoJ-Glyc levels. This first version of the test was validated in retrospective clinical studies showing:
Early diagnosis of ischemia
Prognosis after ischemic event
Predictive value for recurrent events
iSCOR impact
Our results in retrospective clinical studies suggested that ApoJ-Glyc could be a useful marker to map ischemic risk. For this reason, iSCOR can support most of the strategies for the improvement of chest pain management.
Let's get in touch
